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Abstract: The purpose of this study is to examine the gene expression level of glutathione peroxidase 1 (GPx1) in the liver of healthy
and diabetic mice, its localization in the tissue, and structural changes in the liver. In this study, 36 Swiss albino mice were divided
into 3 groups: experimental (diabetic) (n = 15), sham (n = 15), and control (n = 6). Streptozotocin (100 mg/kg) was intraperitoneally
administered to mice in the experimental group. While the gene expression level of GPx1 was determined using the RT-PCR method, its
localization in the liver was determined using an immunohistochemical method. The GPx1 enzyme activity of the experimental group
was lower compared to the sham and control groups (P < 0.05). There was no difference between the experimental and sham groups in
terms of the gene expression of GPx1; however, a statistically insignificant decrease was observed in the experimental group compared
to the sham group. GPx1 had similar immunolocalization in all groups, but GPx1 immunoreactivity was lower in the experimental
group compared to the other groups. Enlargement of hepatocytes and their nuclei as well as the presence of intranuclear inclusion
bodies were observed in the experimental group. In conclusion, diabetes mellitus causes a decrease in the level of GPx1 activity, which
is known to be one of the antioxidant enzymes.
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1. Introduction
Being a result of problems of insulin production and use
in the body, diabetes mellitus is a disease associated with
total or partial insulin deficiency and characterized by
hyperglycemia (1). The formation rate of free radicals in
organisms and their removal rate should be in balance
(oxidative balance). Changing the delicate balance
between free radicals and the antioxidant defense system to
prooxidant and oxidant substances causes the development
of oxidative stress. It has been shown that oxidative stress
causes tissue damage, and it is a factor in the development
of pathological status such as cancer, diabetes, and
atherosclerosis (2). Glutathione peroxidase (GPx; EC
1.11.1.9), which is one of the natural antioxidant defense
systems against free radicals, catalyzes the reduction of
hydrogen peroxide (H2O2) or organic hydroperoxides
into water or alcohols by using reduced glutathione (3).
In this manner, it prevents lipid peroxidation and thus
protects cell membranes from oxidative damage (4). The
distribution of glutathione peroxidase is wide in the tissues
of mammals and the liver is one of the richest sources (5).
Type I diabetes can be triggered for experimental purposes
via a commonly used streptozotocin (STZ) injection in
order to examine the complications caused by diabetes
* Correspondence: turgaydeprem@hotmail.com

and determine treatment approaches (6). It is known
that free fatty acids and various free radical-derived
antioxidants show an increase in diabetes and this increase
causes numerous systemic disorders (7). A decrease in
the quantity of antioxidant parameters in diabetics, such
as vitamins C and E, glutathione, SOD, CAT, and GPx,
shows that oxidative stress can have a significant role in the
pathogenesis of chronic complications of diabetes (8). The
purpose of this study was to examine the gene expression
level of glutathione peroxidase 1 (GPx1) in the livers of
healthy and diabetic (Type I) mice, the localization of
enzyme in the tissue, and structural changes in the liver.
2. Materials and methods
The experimental applications performed on mice
were carried out with approval from the Kafkas
University Animal Experiments Local Ethics Committee
(04.04.2007/13).
Thirty-six 8- to 12-week-old male Swiss albino mice
were used. Mice used in the experiment were divided into
3 groups as experimental (diabetic) (n = 15), sham (n =
15), and control (n = 6). A single dose of 100 mg/kg (9)
STZ (Sigma, St Louis, MO, USA) dissolved in 0.1 M fresh
citrate buffer (pH 4.5) was intraperitoneally administered to
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in total, was used. Once 25 µL of the master mixture was
added into each of the tubes containing mRNA marked
with oligo DT, the tubes were kept in the PCR device at
37 °C for 1 h, at 95 °C for 5 min, and at 4 °C for 5 min in
order to obtain cDNA. Regarding DNA multiplication, 50
µL of master mixture (5 µL of Taq buffer, 1 µL of dNTP,
1 µL of forward primer, 1 µL of reverse primer, 1 µL of
enzyme Taq (Sigma), and 41 µL of nuclease-free water)
was added to each tube containing 2 µL of cDNA and the
tubes were processed in the PCR device at 94 °C for 5 min,
at 50 °C for 1 min, and at 72 °C for 1.5 min (24 cycles
for GPx1 and 30 cycles for β-actin). While the forward
primer was 5’-CCT CAA GTA CGT CCG ACC TG-3’ and
the reverse was 5’-CAA TGT CGT TGC GGC ACA CC-3’
(12) in primer sequences for the GPx1 gene, for β-actin,
the forward was 5’-TCA TGA AGT GTG ACG TTG ACA
TCC GT-3’ and the reverse was 5’-CCT AGA AGC ATT
TGC GGT GCA CGA TG-3’ (13). The end products of the
RT-PCR were processed in a gel electrophoresis device at
100 V for 1 h with a 1.5% agarose gel. The resulting gel
products were assessed by taking their photographs under
UV light. Band densitometries for β-actin and GPx1 in the
gel products were obtained using the Kodak ID program.
The densitometric data of GPx1 were then normalized and
statistically analyzed with reference to β-actin.
SPSS 12.0 was used to conduct the statistical analysis.
Possible differences were determined using Student’s t-test
and analysis of variance. The confidence interval was set at
0.05 for the statistical analysis.
3. Results
It was observed that the mean body weights of the
experimental group decreased daily (P < 0.05). Liver weight
was statistically higher in all days in the experimental
group compared to the sham and control groups (P < 0.05;
Figure 1). Subsequently, depending on time, a regular
increase was observed in liver weight in the experimental
group (P < 0.05). It was determined that the experimental
Liver weight / body weight ratio (x1000)

the mice in the experimental group and 0.1 M citrate buffer
alone was administered to the sham group. No application
was performed on the mice in the control group. The starttime of the experiment was labeled as “0”, and the body
weights of mice were measured after 8 h of hunger on days
0, 3, 7, 15, 21, and 30. Afterwards, blood glucose values were
determined using a manual glucose meter (Accu-Chek-Go,
Roche, Basel, Switzerland) in blood taken from the orbital
sinuses using a hematocrit tube. Blood glucose values after
8 h of hunger were measured 72 h after STZ administration,
and mice having values of 200 mg/dL and above were
accepted as diabetic (9) and included in the study.
Liver tissue samples were taken by euthanizing mice
with cervical dislocation under ether anesthesia on days
3, 15, and 30. The liver tissue taken for molecular analysis
was homogenized in Tri-Reagent (Sigma) and kept at 4
°C until the day of analysis. Liver tissue samples allocated
for histological and immunohistochemical analyses were
fixed in Bouin and formol-alcohol solutions.
Some liver tissue samples were blocked in paraffin
after routine tissue follow-up and 6-µm-thick sections
were taken. Crossman’s triple staining, hematoxylin-eosin
staining, and periodic acid–Schiff staining were applied.
The avidin-biotin-peroxidase complex technique was
performed in order to investigate the immunohistochemical
distribution of GPx1 in the liver tissue. The sections were
incubated with anti-GPx1 (Abcam-ab22604) (1:3000) at
room temperature for 1 h. After irrigation with phosphate
buffered saline (PBS), the biotinylated secondary antibody
(Ultravision Detection System Anti-Rabbit, Biotinylated
Goat Anti-Rabbit, LabVision-510.991.2800), against the
type for which the primary antibody is produced, was
applied to sections for 30 min. Then, after further irrigation
with PBS, streptavidin-horse radish peroxidase was added
to the sections and kept at room temperature for 30 min.
After irrigation with PBS again, the DAB-H2O2 technique
was used for chromogen application. The preparations
were examined using a BX-051 Olympus microscope and
their photographs were taken.
GPx enzyme activity was measured according to the
method of Matkovics et al. (10). Total RNA isolation,
obtained as a result of modification of the guanidine
isothiocyanate/phenol-chloroform method described
by Chomczynski and Sacci (11), was carried out using
Tri-Reagent (Sigma). The amount of RNA per microliter
was measured using a spectrophotometer at 260 nm
wavelength. mRNAs were obtained using Oligo dT primers
(Promega, Madison, WI, USA). An MMLV RT master
mixture was prepared in order to obtain cDNA (Moloney
Murine Leukemia Virus Reverse Transcriptase). For each
sample, 8 µL of MMLV enzyme buffer, 8 µL of dNTP
(Sigma), 1 µL of rRNAsin (Promega), 1.6 µL of MMLVRT enzyme (Promega), and 6.4 µL of NF water, at 25 µL
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Figure 1. Comparison of liver weights between groups (* = P <
0.05).
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group had lower GPx1 enzyme activity in the liver tissue
compared to the sham and control groups (P < 0.05).
The livers of mice in the sham and control groups were
observed to have normal histological structure (Figure
2A). On day 3, the outer surfaces of some cell nuclei
became irregular in the liver tissue of the experimental
group, and lesions like swelling were found in the nuclei.
A significant enlargement (megalocytosis) was observed
in the hepatocytes and nuclei of the mice livers in the
experimental group on day 15 compared to day 3. Cell
nuclei also became irregular during this period (Figure
2B). In contrast to the lesions identified on day 3,
cytoplasmic invaginations with eosinophilic character and
globular structure in the nucleus were encountered on day
15 (Figure 2B). Histological findings of the liver sections
of the experimental group on day 30 were similar to those
obtained on day 15 (Figure 2C).
GPx1 immunoreactivity was observed in all of
the groups: sham, control, and diabetic. On day 3 of
the experiment, periacinar staining was seen in all of
the groups. The staining was present variably in both
nuclei and cytoplasm (Figure 3A). The staining in the
hepatocytes located around the Kiernan space was more

intense compared to those located in the periacinar
regions (Figure 3B). Staining characteristics for all the
treatment days/groups were similar to each other and
some cells showed cytoplasmic and/or nuclear staining
throughout the sections (Figure 3C). Moreover, GPx1
immunoreactivity in the diabetic group (Figure 4A) was
lower compared to the sham group on day 15 (Figure 4B).
GPx1 immunoreactivity findings in the liver on day 30
were similar to those obtained on days 3 and 15.
No statistically significant difference was observed
between the experimental and sham groups in terms of
β-actin (control) gene expression in the liver tissue (Figure
5A). Even though there was no statistical difference
between the sham and diabetic groups in terms of GPx1
gene expression on day 3, GPx1 gene expression was higher
at a statistically insignificant level in the diabetic group on
day 3; however, although there was no statistical difference
in the diabetic group in terms of GPx1 gene expression
between days 15 and 30, GPx1 gene expression decreased
at a statistically insignificant level in the diabetic group
(Table; Figure 5B). The experimental group also had a
statistically insignificant decrease in GPx1 gene expression
over the time period of the study (Table).

Figure 2. A) Histological view of livers of mice in the control group, with triple staining. Bar = 50 µm. B) Histological view of livers of
diabetic mice on day 15. Arrow head = nuclei of impaired hepatocyte, thin arrow = spherical or oval eosinophilic inclusion bodies in
nucleus, bar = 50 µm. C) Histological view of livers of diabetic mice on day 30. Thick arrow = megalocytosis in hepatocytes, thin arrow
= impaired nuclei of hepatocytes, and bar = 50 µm.
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Figure 3. A) Intense GPx1 immunoreactivity in the periacinar hepatocytes in the experimental group on day 3. Arrows = vena centralis,
bar = 100 µm. B) Intense GPx1 immunoreactivity in hepatocytes around the Kiernan space of livers of mice in the experimental group
on day 3. Arrow = hepatocytes, bar = 100 µm. C) Cytoplasmic and nuclear GPx1 immunoreactivity in hepatocytes of mouse livers in the
sham group on day 15. Arrows = cytoplasmic GPx1 immunoreactivity, arrow head = cytoplasmic and nuclear GPx1 immunoreactivity,
bar = 50 µm.

Figure 4. A) GPx1 immunoreactivity in the livers of mice in the experimental group on day 15. B) GPx1 immunoreactivity in the livers
of mice in the sham group on day 15. Bar = 50 µm.

4. Discussion
Studies conducted on body weight changes in diabetes
(14–17) revealed different results. Watkins et al. (17)
reported that there was no difference between the control
and diabetic groups during a period of 42 days in terms
of the mean body weight of mice. Fujita et al. (15) stated
a significant decrease in the body weight in STZ diabetic
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mice compared to the control. Doi et al. (14) stated that
the body weight of diabetic mice decreased compared
to the control mice at the end of a 4-week-long period,
and the body weights of the STZ group increased during
the study period. Imaeda et al. (16) indicated that there
was a decrease in the body weights of mice under STZ
administration, especially on day 7. This study revealed a
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Figure 5. A) β-Actin gene RT-PCR results (product size: 285 base pairs). B) GPx1 gene RT-PCR results (product size: 197 base pairs).
PK = positive control, NK = negative control, L = 100-bp DNA ladder.

Table. Comparison of mean GPx1 gene expression levels of groups by day.
GPx1 gene expression levels (arbitrary units)
Day 3

Day 15

Group

Number
(n)

Mean rank

SD

Experimental

3

0.80

0.49

Sham

3

0.67

0.23

F-value
0.16ns

Day 30

Mean rank

SD

0.82

0.42

0.91

0.21

F-value
0.11ns

Mean rank

SD

0.65

0.51

0.69

0.06

F-value
0.02ns

SD = Standard deviation, ns = not significant.

decrease in the mean body weight of STZ diabetic mice
during the 4-week-long experimental period, and the
fact that this loss of body weight became evident on day
7 shows a parallelism with the findings of Imaeda et al.
(16). Researchers (18) stated that weight loss in diabetes
was observed during the lipolysis and gluconeogenesis
processes occurring while cells obtain glucose.
Reports stated that experimental diabetes increased
(14,19), decreased (18), or did not change (17) liver
weight. We determined in this study that liver weight
increased in the diabetic group compared to the sham
and control groups, and the liver weight of the diabetic
group increased during the period, as well. Our results are
parallel to the results of Cho et al. (19) and Doi et al. (14).
While Garg et al. (20) reported an increase in GPx
enzyme activity in the diabetic liver compared to the
control and Can et al. (21) reported a decrease in GPx
enzyme activity in the diabetic liver, Kinalski et al. (22)
found no difference. In this study, we determined that GPx
activity in STZ diabetic mice was lower compared to the
control and sham groups, which supported the results of
researchers stating that enzyme activity decreased (19,21).
As reported by Bonnefont-Rousselot et al. (23), it was
thought that the decrease in GPx level could be associated

with the fact that antioxidant enzymes became inactive as
a result of glycosylation due to hyperglycemia in diabetes.
In their 4-week-long and 6-week-long studies, Otsuka
et al. (24) determined using the RT-PCR method that GPx
mRNA level considerably decreased in the livers of diabetic
rats compared to control rats. Cho et al. (19) examined
hepatic antioxidant enzyme activities and lipid profiles of
diabetic rats via northern blot analysis and reported that
hepatic GPx mRNA concentrations in the diabetic group
slightly decreased compared to the control even though
this was not statistically significant. This study revealed
that although there was no statistical difference between
the sham group and the diabetic group on day 3, the
concentration was higher in the diabetic group. However,
it decreased in the diabetic group even though there was
no statistical difference on days 15 and 30. Results obtained
on days 15 and 30 show parallelism with those of the study
conducted by Cho et al. (19). A statistically insignificant
decrease was determined in GPx1 gene expression in the
experimental group on day 30 compared to days 3 and 15
in this study. The reason for this statistically insignificant
decrease was thought to be associated with the period.
Watkins et al. (17), who examined the livers of STZ
diabetic mice at the electron microscopic level, reported
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swelling in the hepatic sinuses, especially on the first and
third days, and a visible enlargement between hepatocyte
boundaries. While some researchers developing diabetes in
mice using STZ (14,25) noted that the hepatocyte nucleus
area increased, some (25,26) reported that the size of the
cell increased (hypertrophy). Honjo et al. (26) revealed that
cytoplasmic invaginations formed in the hepatocyte nucleus.
Doi et al. (14) reported that the hepatocyte nucleus area in
STZ diabetic mice was nearly twice as large as the controls
and showed irregular structures. Can et al. (21) stated that
the liver cellular layers of diabetic rats became impaired
due to degeneration of hepatocytes, most liver cells seemed
vacuolated, and swollen hepatocytes included eosinophilic
intracytoplasmic inclusions. In this study, it was observed
that the cell took the shape of a signet ring by pushing aside
nuclei of some liver hepatocytes in the diabetic group. The
outer sides of these cell nuclei became irregular, and swellinglike lesions were also found in the nuclei. The fact that an
enlargement (megalocytosis) was observed in hepatocytes
and their nuclei in the livers of the experimental group on day
15 compared to day 3 was in line with the results of Laguens et
al. (25) and Doi et al. (14). Unlike the lesions detected on day
3, cytoplasmic invaginations with intranuclear eosinophilic
character and globular structure were frequently found,
which is in line with the data of Can et al. (21).
Yoshimura et al. (27) reported that in terms of
immunohistochemistry, GPx was diffusely localized in the
cytoplasm of hepatocytes in the livers of rats, a stronger
staining occurred in the periphery of the hepatic lobe
compared to the central zone around the central vein,
and endothelial cells around the sinusoids and Kupffer
cells were not stained. Asayama et al. (28) indicated
that cellular GPx was found in the cytoplasm, nuclei,
mitochondria, and other organelles of the hepatocytes
of rats using the immunogold technique. Asayama et al.
(29) stated that GPx1 was immunohistochemically stained
with a similar concentration in the centrilobular area and
periphery around the central vein in the liver hepatocyte
cells of fetal and neonatal rats. Utsunomiya et al. (30)
explained in their study that the immunoreactivity of GPx

was stronger especially in the cytosol of hepatocytes in
the periportal zone, and GPx gave a positive reaction in
both the cytoplasm and nuclei of hepatocytes. In a study
(27) conducted using immunoelectron microscopy, GPx
was observed to be intensely localized in the cytoplasm
of the periportal hepatocytes in rat liver. After a literature
review, it was determined that there was no information
about the immunoreactivity of GPx1 in diabetes; GPx1
showed similar immunolocalization in the livers of the
control, sham, and diabetic groups in this study, and
GPx1 immunoreactivity in the diabetic group was lower
compared to the sham group. GPx1 immunoreactivity,
which showed diffuse cytoplasmic and/or nuclear staining,
was generally similar in our study to that reported by
Asayama et al. (29).
GPx1 immunoreactivity was observed to be more
intense in hepatocytes around the vena centralis and
Kiernan space. However, GPx1 immunoreactivity was
not observed in vein endothelial cells of the vena centralis
and the endothelial and connective tissue of veins in the
Kiernan space. Our results support the data of Yoshimura
et al. (27).
In conclusion, it was observed that diabetes mellitus
caused a significant decrease in the tissue activity in the
GPx gene expression in the liver that is not reflected by the
statistics. We are of the opinion that the results obtained
in our study may vary according to the period of the
experiment, species of the experimental animals used, and
individual differences. We suggest that the results of this
study will shed light for new studies to be conducted via
advanced techniques in order to clarify the relationship
between diabetes mellitus and antioxidants.
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